First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV in Healthy Adults
NCT04896086
Completed
Background: Influenza (flu) is a contagious respiratory illness. It is caused by influenza viruses that infect the nose, throat, and sometimes the lungs. Vaccines are given to teach the body to prevent or fight infection. Researchers want to study a new vaccine to prevent the seasonal flu. Objective: To see if the FluMos-v1 vaccine is safe and how the body responds to it. Eligibility: Healthy adults ages 18-50 years inclusive were enrolled. Design: Participants were screened through a sep... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
04/14/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Influenza, Seasonal Influenza
Register for Updates
Absorption and Tolerability of Injectable Administration of Niagen®+, as Compared to NAD+
NCT06919328
Recruiting
This study evaluates the subjective effects of injection administration of NR on healthy adult populations.
Gender:
ALL
Ages:
Between 40 years and 65 years
Trial Updated:
04/07/2025
Locations: Nutraceuticals Research Institute, Huntsville, Alabama
Conditions: Healthy Aging
Register for Updates
Iterative Redesign of a Multifaceted Implementation Strategy for a School-based Behavioral Skills Intervention (RUBI)
NCT06508515
Recruiting
The increased prevalence of autism spectrum disorder (1 in 36 youth) in the United States along with the exorbitant cost of care of supporting one autistic individual with and without intellectual disability across their lifespan ($2.4 and $1.4 million, respectively) creates a sense of urgency to improve outcomes for autistic youth. Schools are the primary setting in which autistic children receive intervention. Despite a growing array of evidence-based interventions (EBI) such as behavioral man... Read More
Gender:
ALL
Ages:
5 years and above
Trial Updated:
03/25/2025
Locations: University of Washington, Seattle, Washington
Conditions: Autism Spectrum Disorder
Register for Updates
Effects of Photobiomodulation (PBM) on Pain After Presentation of Aphthous Ulcers in Pediatric Dental Patients
NCT06819033
Recruiting
The purpose of this study is to compare the efficacy of laser photobiomodulation and "Magic Mouthwash" for treatment of pain in pediatric patients with aphthous ulcers , to assess how photobiomodulation influences the rate of healing of aphthous ulcers in pediatric patients and to measure changes in pain levels reported by pediatric patients undergoing photobiomodulation treatment for aphthous ulcers.
Gender:
ALL
Ages:
Between 5 years and 17 years
Trial Updated:
03/20/2025
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Aphthous Ulcer
Register for Updates
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
NCT06179303
Recruiting
This phase II trial tests the accuracy of functional imaging (FFNP)-positron emission tomography (PET)/computed tomography (CT) to predict response to abemaciclib plus endocrine therapy. Abemaciclib is a drug used to treat certain types of hormone receptor positive (HR+), HER2 negative breast cancer. Abemaciclib blocks certain proteins, which may help keep tumor cells from growing. Endocrine therapy adds, blocks, or removes hormones that can cause cancer to grow. FFNP PET imaging is a form of x-... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: Siteman Cancer Center at Washington University, Saint Louis, Missouri +1 locations
Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable HER2-Negative Breast Carcinoma, Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma
Register for Updates
Contributions to Hypertension With Androgen Deprivation Therapy
NCT05700903
Recruiting
This study plans to learn more about contributors to high blood pressure in men who undergo androgen deprivation therapy (ADT) to treat prostate cancer. Prostate cancer is the most common non-skin cancer in men, affecting approximately 1 in 8 American men and its primary treatment is through the use of ADT. However, ADT increases the likelihood of developing heart disease including high blood pressure. This study will determine if dysfunction of the nervous system and/or kidneys occurs in men un... Read More
Gender:
MALE
Ages:
40 years and above
Trial Updated:
03/06/2025
Locations: UCHealth University of Colorado Hospital, Aurora, Colorado
Conditions: Androgen Deprivation Therapy, Prostate Cancer, Hypertension, Autonomic Dysfunction, Renal Disease
Register for Updates
Work of Breathing Assessment in Triage Scale
NCT05479929
Active Not Recruiting
The proposed research study will be a prospective observational study designed to validate the Canadian Triage Assessment Scale (CTAS) in regard to work of breathing in patients in the emergency department. The investigators will assess inter-rater agreement between nurses \& emergency physicians for assessment of work of breathing.
Gender:
ALL
Ages:
All
Trial Updated:
03/04/2025
Locations: CHRISTUS Spohn Hospital, Corpus Christi, Texas
Conditions: Shortness of Breath, Respiratory Symptoms, Cough, Difficulty Breathing, Hypoxemia
Register for Updates
A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme
NCT06019728
Completed
This Phase 4 study will evaluate the safety and tolerability of Fabrazyme at current approved dose with increases in the infusion rate and reduced infusion volume. This study aims to generate data to provide the guidance on how infusion rate can be safely increased and minimize the burden of the life-long treatment with Fabrazyme.
Gender:
ALL
Ages:
Between 2 years and 65 years
Trial Updated:
02/24/2025
Locations: UCLA Medical Center Site Number : 1003, Santa Monica, California +4 locations
Conditions: Fabry's Disease
Register for Updates
Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery
NCT02949284
Active Not Recruiting
This randomized phase II trial studies how well androgen receptor antagonist ARN-509 works with or without abiraterone acetate, gonadotropin-releasing hormone agonist, and prednisone in treating patients with high-risk prostate cancer undergoing surgery. Androgen can cause the growth of prostate cancer cells. Hormone therapy using androgen receptor antagonist ARN-509, abiraterone acetate, and gonadotropin-releasing hormone analog (GnRH agonist) may fight prostate cancer by lowering the levels of... Read More
Gender:
MALE
Ages:
All
Trial Updated:
02/24/2025
Locations: Yale Cancer Center, New Haven, Connecticut +1 locations
Conditions: Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma
Register for Updates
Yoga for Mental Health in Parkinson's Patients
NCT05335850
Completed
This study is a waitlisted randomized controlled trial. We aim to assess the level of compliance for those learning the intervention and to evaluate the impact of the practice on neuropsychological and somatic outcomes using validated scales. Enrollment into the study will be ongoing until we are able to get a sufficient sample size as described in the "Statistical Consideration" section. Upon enrollment and randomization, surveys will be administered to both the intervention and control groups... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: Beth Israel Deaconess Medical Centre, Boston, Massachusetts
Conditions: Stress, Anxiety, Depression, Parkinson Disease
Register for Updates
Effectiveness of Qualia NAD+ Supplementation on NAD Levels
NCT06812416
Completed
The current study is designed as a randomized double-blind placebo-controlled parallel trial. It aims to investigate the efficacy of Qualia NAD+ on intracellular NAD levels in blood samples (primary outcomes) and health-related quality of life (secondary outcomes) in an adult population experiencing moderate to severe joint pain between ages of 40 and 65 years.
Gender:
ALL
Ages:
Between 40 years and 65 years
Trial Updated:
02/02/2025
Locations: Remote Study, Carlsbad, California
Conditions: Intracellular NAD+ Levels
Register for Updates
Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity and Safety With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older
NCT05608005
Completed
VAM00001 is a Phase I/II, randomized, modified double-blind, multi-center study. The purpose of this study is to compare 2 dose levels of Panblok H7 (dose 1 and dose 2 of rHA) with a standard squalene dose of adjuvant MF59 to Panblok H7 (dose 3) unadjuvanted in approximately 700 adult participants in order to select one dose formulation to be used for further clinical development. The randomization ratio will be 3:3:1 for Panblok H7 (dose 1) + MF59, Panblok H7 (dose 2) + MF59, and Panblok H7 (d... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Centricity Research-Mesa Site Number : 8400006, Mesa, Arizona +15 locations
Conditions: Healthy Volunteers, Influenza
Register for Updates